ZBH logo

Zimmer Biomet Holdings, Inc. (ZBH) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Zimmer Biomet Holdings, Inc. (ZBH), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve $0 piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 50/100 puan alıyor.

Son analiz: 9 Şub 2026
50/100 AI Puanı

Zimmer Biomet Holdings, Inc. (ZBH) Sağlık ve Boru Hattı Genel Bakışı

CEOIvan Tornos
Çalışanlar17000
MerkezWarsaw, IN, US
Halka Arz Yılı2001
SektörHealthcare

Zimmer Biomet, a global leader in musculoskeletal healthcare since 1927, offers a comprehensive portfolio of innovative orthopedic and dental solutions. With a robust 10.1% profit margin and a 1.07% dividend yield, ZBH presents a notable research candidate within a growing market.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 9 Şub 2026

Yatırım Tezi

Zimmer Biomet presents a notable research candidate driven by its leading position in the growing musculoskeletal healthcare market. The company's diverse product portfolio, including orthopedic reconstructive products, S.E.T. products, and dental implants, caters to a wide range of patient needs. With a solid profit margin of 10.1% and a dividend yield of 1.07%, ZBH offers a blend of growth and income potential. Key value drivers include the aging global population, increasing demand for orthopedic procedures, and technological advancements in surgical techniques and implant materials. Growth catalysts include expanding into emerging markets and strategic acquisitions to broaden its product offerings. Investing in ZBH offers exposure to a stable and growing healthcare segment with a proven market leader.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $17.82 billion reflects Zimmer Biomet's significant presence in the musculoskeletal healthcare market.
  • P/E ratio of 22.12 indicates investor confidence in the company's earnings potential.
  • Gross margin of 71.4% demonstrates efficient cost management and strong pricing power.
  • Profit margin of 10.1% showcases the company's ability to generate profits from its operations.
  • Dividend yield of 1.07% provides a steady income stream for investors.

Rakipler & Benzerleri

Güçlü Yönler

  • Strong market position in the musculoskeletal healthcare industry.
  • Diverse product portfolio catering to a wide range of orthopedic and dental needs.
  • Established brand reputation and global presence.
  • Consistent investment in research and development.

Zayıflıklar

  • Exposure to regulatory risks and healthcare reforms.
  • Dependence on reimbursement policies and pricing pressures.
  • Potential for product recalls and liability claims.
  • Competition from other major players in the orthopedic device market.

Katalizörler

  • Upcoming: New product launches in the orthopedic reconstructive and S.E.T. segments.
  • Ongoing: Expansion into emerging markets, particularly in Asia Pacific.
  • Ongoing: Strategic acquisitions to broaden product portfolio and market reach.
  • Ongoing: Continued investment in research and development to drive innovation.
  • Ongoing: Growing demand for orthopedic procedures due to aging population and rising obesity rates.

Riskler

  • Potential: Regulatory changes and healthcare reforms impacting reimbursement policies.
  • Potential: Product recalls and liability claims related to implant failures.
  • Ongoing: Competition from other major players in the orthopedic device market.
  • Potential: Economic downturns and healthcare spending cuts affecting demand for elective procedures.
  • Potential: Technological disruptions and obsolescence of existing products.

Büyüme Fırsatları

  • Expanding into Emerging Markets: Zimmer Biomet has a significant opportunity to expand its presence in emerging markets, such as China and India, where the demand for orthopedic procedures is rapidly increasing due to aging populations and rising disposable incomes. These markets represent a substantial growth opportunity with the potential to significantly boost revenue over the next 5-10 years. Success in these markets will require tailored product offerings and strategic partnerships with local healthcare providers.
  • Technological Advancements in Robotics: Zimmer Biomet can leverage technological advancements in robotics to enhance surgical precision and improve patient outcomes. Investing in robotic-assisted surgical platforms and integrating them with its existing product portfolio can attract surgeons and hospitals seeking to adopt cutting-edge technologies. The market for surgical robots is projected to grow significantly over the next decade, presenting a substantial growth opportunity for Zimmer Biomet.
  • Strategic Acquisitions: Zimmer Biomet can pursue strategic acquisitions to broaden its product portfolio and expand its market reach. Acquiring companies with complementary technologies or specialized expertise in niche areas of orthopedics can strengthen Zimmer Biomet's competitive position and drive revenue growth. Identifying and integrating synergistic acquisitions will be crucial for realizing the full potential of this growth strategy. This is an ongoing opportunity.
  • Focus on Personalized Medicine: Zimmer Biomet can capitalize on the growing trend of personalized medicine by developing customized implants and surgical solutions tailored to individual patient needs. Utilizing advanced imaging technologies and data analytics to create patient-specific implants can improve surgical outcomes and patient satisfaction. This approach requires significant investment in research and development but offers a substantial competitive advantage.
  • Expanding S.E.T. Product Line: Zimmer Biomet has the opportunity to further expand its S.E.T. (Sports Medicine, Biologics, Extremities, and Trauma) product line. The sports medicine market is experiencing growth due to increased participation in sports and recreational activities, leading to more injuries. Developing innovative biologics and trauma solutions can address unmet clinical needs and drive revenue growth. This area requires continuous innovation and adaptation to evolving patient needs.

Fırsatlar

  • Expanding into emerging markets with high growth potential.
  • Leveraging technological advancements in robotics and personalized medicine.
  • Pursuing strategic acquisitions to broaden product offerings.
  • Developing innovative solutions for unmet clinical needs.

Tehditler

  • Increasing competition from existing and new market entrants.
  • Evolving regulatory landscape and compliance requirements.
  • Economic downturns and healthcare spending cuts.
  • Technological disruptions and obsolescence of existing products.

Rekabet Avantajları

  • Strong brand reputation and established market presence.
  • Extensive product portfolio catering to diverse orthopedic and dental needs.
  • Significant investment in research and development, leading to innovative products.
  • Established relationships with surgeons and hospitals.
  • High switching costs for customers due to the complexity and critical nature of orthopedic procedures.

ZBH Hakkında

Zimmer Biomet Holdings, Inc. stands as a prominent player in the musculoskeletal healthcare sector, offering a wide array of products and services across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Founded in 1927 and headquartered in Warsaw, Indiana, the company has a rich history of innovation and commitment to improving patient outcomes. Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive products, including knee and hip implants, which are crucial for patients suffering from arthritis and other degenerative joint conditions. Their S.E.T. (Sports Medicine, Biologics, Extremities, and Trauma) products address a broad spectrum of orthopedic needs, from sports-related injuries to complex trauma cases. The company also offers spine products, dental reconstructive implants, and bone cement products. Zimmer Biomet serves a diverse customer base, including orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, and healthcare purchasing organizations. The company's evolution reflects a dedication to advancing musculoskeletal care through continuous innovation and strategic acquisitions. Formerly known as Zimmer Holdings, Inc., the company rebranded to Zimmer Biomet Holdings, Inc. in June 2015, signifying its expanded portfolio and global reach.

Ne Yaparlar

  • Designs, manufactures, and markets orthopedic reconstructive products.
  • Offers knee and hip replacement solutions.
  • Provides S.E.T. (Sports Medicine, Biologics, Extremities, and Trauma) products.
  • Develops and distributes spine products, including medical devices and surgical instruments.
  • Offers dental reconstructive implants and related prosthetic products.
  • Provides products for face and skull reconstruction.
  • Offers robotic, surgical and bone cement products.

İş Modeli

  • Develops and manufactures a wide range of orthopedic and dental products.
  • Sells products directly to hospitals, surgeons, and healthcare providers.
  • Generates revenue through product sales and related services.
  • Invests in research and development to innovate new products and improve existing ones.

Sektör Bağlamı

Zimmer Biomet operates within the medical device industry, specifically focusing on the musculoskeletal segment. This industry is characterized by continuous innovation, increasing regulatory scrutiny, and evolving patient needs. The global orthopedic device market is projected to grow, driven by the aging population, rising obesity rates, and advancements in surgical technologies. Zimmer Biomet competes with other major players in the orthopedic device market, such as DGX, DXCM, ILMN, INCY, and LH, each vying for market share through product innovation, strategic partnerships, and geographic expansion. The industry is also influenced by healthcare reforms and cost containment pressures, requiring companies to demonstrate value and efficiency.

Kilit Müşteriler

  • Orthopedic surgeons
  • Neurosurgeons
  • Oral surgeons
  • Dentists
  • Hospitals and healthcare facilities
AI Güveni: 72% Güncellendi: 9 Şub 2026

Finansallar

Grafik & Bilgi

Zimmer Biomet Holdings, Inc. (ZBH) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

ZBH için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

ZBH için Wall Street fiyat hedefi analizi.

MoonshotScore

50/100

Bu puan ne anlama geliyor?

MoonshotScore, ZBH'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

ZBH Hakkında Sıkça Sorulan Sorular

ZBH için değerlendirilmesi gereken temel faktörler nelerdir?

Zimmer Biomet Holdings, Inc. (ZBH) şu anda yapay zeka skoru 50/100, orta puanı gösteriyor. Temel güçlü yan: Strong market position in the musculoskeletal healthcare industry.. İzlenmesi gereken birincil risk: Potential: Regulatory changes and healthcare reforms impacting reimbursement policies.. Bu bir finansal tavsiye değildir.

ZBH MoonshotScore'u nedir?

ZBH şu anda MoonshotScore'da 50/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

ZBH verileri ne sıklıkla güncellenir?

ZBH fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler ZBH hakkında ne diyor?

ZBH için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

ZBH'a yatırım yapmanın riskleri nelerdir?

ZBH için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Regulatory changes and healthcare reforms impacting reimbursement policies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

ZBH'ın P/E oranı nedir?

ZBH için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ZBH'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

ZBH aşırı değerli mi, yoksa düşük değerli mi?

Zimmer Biomet Holdings, Inc. (ZBH)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

ZBH'ın temettü verimi nedir?

Zimmer Biomet Holdings, Inc. (ZBH) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Stock data pending update.
  • The analysis is based on the provided information and publicly available data.
  • Investment decisions should be made based on individual risk tolerance and financial circumstances.
Veri Kaynakları

Popüler Hisseler